Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tricyclic antidepressants effective for headaches, but comparative trials would be more convincing

This article was originally published in Scrip

Executive Summary

Tricyclic antidepressants have been used for treating headaches as an unlicensed indication since the 1960s (as well as being recommended for this in European and US neurology clinical guidelines), but their role was given a further boost in a meta-analysis study published in the BMJ last week. Despite evidence from the meta-analysis that tricyclics are effective preventative treatments for headache and migraine, the real clinical proof of their effectiveness is unlikely to be generated by the pharmaceutical industry, commentators says.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC010676

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel